Novel molecular-based management strategies, such as RET-PTC, RAS, BRAF (V600E), and TERT mutations for thyroid nodules and thyroid cancer are the most exciting developments in thyroid-cancer medicine [26]. This evidence concerns the gene RET and thyroid gland carcinoma.